Shuttle Pharmaceuticals Holdings, Inc.

Name: Shuttle Pharmaceuticals Holdings, Inc. standardized financial statements, quarterly
Creator: Listed

SHPHNasdaqCIK 1757499HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.9m, Q2 FY2026

Net income−$3.1m, Q2 FY2026

Shuttle Pharmaceuticals Holdings, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$k	1,045	710	586	646	1,401	986	1,574	1,026	943	512	267	55.7
Operating income	$k	(1,599)	(1,283)	(1,385)	(1,483)	(3,052)	(1,777)	(2,951)	(3,910)	(2,267)	(2,788)	(2,217)	(3,950)
Interest expense	$k	623	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(1,793)	(1,641)	(1,731)	(2,031)	(3,784)	(1,598)	(3,053)	(3,706)	(2,347)	(2,615)	(2,152)	(3,146)
Diluted EPS	$ per share	(0.91)	not reported	(0.83)	(24.12)	(39.83)	not reported	(7.60)	(32.91)	(1.05)	not reported	(0.43)	(3.10)
Basic EPS	$ per share	(0.91)	not reported	(0.83)	(24.12)	(39.83)	not reported	(7.60)	(32.91)	(1.05)	not reported	(0.43)	(3.10)

Balance sheet

Cash and equivalents$90.2k, Q2 FY2026

Shareholders' equity$19.2m, Q2 FY2026

Shuttle Pharmaceuticals Holdings, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	3.9	2.6	1.4	0.7	0.2	1.9	4.5	4.8	2.1	0.3	1.1	0.1
Current assets	$m	7.0	5.6	4.4	2.5	0.4	2.2	5.0	5.2	3.3	0.5	2.5	0.4
Total assets	$m	7.4	6.0	4.8	2.8	0.7	2.5	5.3	5.5	3.5	10.5	11.8	22.8
Current liabilities	$m	0.8	1.0	1.5	1.4	1.7	1.5	1.8	1.7	2.0	8.0	8.3	3.5
Total liabilities	$m	1.8	1.9	2.0	2.0	2.0	1.8	2.0	1.9	2.1	8.2	8.5	3.6
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	5.6	4.1	2.8	0.8	(1.3)	0.7	3.3	3.6	1.4	2.3	3.3	19.2

Cash flow

Operating cash flow−$567.6k, Q2 FY2026

Capital expenditure$0, Q4 FY2023

Shuttle Pharmaceuticals Holdings, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,535)	(1,062)	(1,239)	(1,399)	(1,999)	(2,690)	(2,527)	(3,355)	(2,627)	(973)	(2,417)	(568)
Capital expenditure	$k	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)1.02m, Q2 FY2026

Shuttle Pharmaceuticals Holdings, Inc., shares, quarterly
Line item	Unit	period not labelled2022-06-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	9,313	1,705	1,780	1,970	2,076	84.2	95.0	402	113	2,234	5,032	1,015

Shares outstanding: 4.76m at Sep 21, 2026, from the cover of the 10-Q filed Sep 24, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.